|Disruptive technology is new technology that unexpectedly displaces an established technology. There are two categories of disruptive technology, sustaining and disruptive, both which are transformative, yet one type is moreso than the other.
Sustaining technology relies on incremental improvements to an already established technology, whereas disruptive technology lacks refinement, appeals to a more limited audience, and may not yet have a proven practical application. Sometimes, as a disruptive technology is adopted, it becomes sustaining.
Such is the case with the LDTD
Since initial launch, it has been adopted by 2/3 of global pharma as an accepted bioanalytical technique, especially for the CYP inhibition assays.
Now they are looking at other new high throughput screening applications for it: other ADME/Tox assays and enzyme assays, biomarkers, GPCR endpoints, phenotypic screenings, etc.
|Despite it’s proven advantages, it’s not for everyone. Only organizations that are receptive or may be considered “disruptive innovation leaning” are drawn to it, evaluate and adopt it. After years of collaborating with pharma review teams, we have learned that the firms that adopt LDTD share certain values in common:
▪ Share a widely-held consensus internally about the benefits that the LDTD affords
One such company, Bristol-Myers Squibb, at SLAS 2015, in search of new high speed MS technologies, assessed LDTD-MS/MS coupled with disruptive acoustic sample deposition sound energy liquid handling from LabCyte to increase throughput and reduce costs even further. Perhaps you’ve heard.
|A little more about LDTD and then how to learn more
LDTD is the high throughput ion source, matrix-free and solvent-free, used to produce sub-ssecond per sample readout with smaller volume requirements. LDTD combines ultra-fast thermal desorption with efficient gas-phase APCI. By coupling acoustic sample deposition with LDTD sample readout as fast as 1.9 seconds/well is achieved.
What to know more? Choose from …
* Watch the new 3 minute video